Harrow is Monday's IBD Stock Of The Day. The biotech stock is setting up to tack a handle onto a seven-week cup.

Boll stated, "we are updating our full year revenue outlook to a range of $270 million to $280 million." He noted, "While our original target is still within reach, this new range is one I believe we ...